Acute and nine-month clinical outcomes after "suboptimal" coronary stenting
Results from the STent anti-thrombotic regimen study (STARS) registry
Donald E. Cutlip, MD, FACC*,
Martin B. Leon, MD, FACC ,
Kalon K. L. Ho, MD, MSc, FACC ,
Paul C. Gordon, MD, FACC ,
Alessandro Giambartolomei, MD, FACC||,
Daniel J. Diver, MD, FACC¶,
David M. Lasorda, DO, FACC#,
David O. Williams, MD, FACC**,
Michelle M. Fitzpatrick, RN,
April Desjardin, MS,
Jeffrey J. Popma, MD, FACC,
Richard E. Kuntz, MD, MSc,
Donald S. Baim, MD, FACC for the STent Anti-thrombotic Regimen Study Investigators
* University of Rochester Medical Center, Rochester, New York, USA
Washington Hospital Center, Washington, DC, USA
Beth Israel Deaconess Medical Center, Boston, Massachusetts, USA
Miriam Hospital, Providence, Rhode Island, USA
|| St. Joseph’s Hospital, Syracuse, New York, USA
¶ Georgetown Medical Center, Washington, DC, USA
# Allegheny University Hospitals, Allegheny General Hospital, Pittsburgh, Pennsylvania, USA
** Rhode Island Hospital, Providence, Rhode Island, USA
Brigham and Women’s Hospital, Boston, Massachusetts, USA
View larger version (17K):
[in a new window]
|
Figure 1 Cumulative distribution frequency of percent diameter stenosis at baseline (pre) and after final stent postdilation (post). At baseline, there is no difference in stenosis severity for registry compared with randomized patients. The final diameter stenosis is slightly, but significantly, worse for registry patients.
|
|
View larger version (12K):
[in a new window]
|
Figure 2 Estimated freedom from TVF for registry compared with randomized patients. There is a significant increase in TVF events early for registry patients with further separation of the survival curves during the first year, consistent with increased frequency of periprocedural MI as well as later target vessel revascularization.
|
|
|
